Baidu
map

J Am Acad Dermatol:阿普斯特可有效治疗中重度头皮银屑病

2021-05-03 MedSci原创 MedSci原创

许多银屑病患者被头皮等部位的瘙痒症状所困扰。近日,一项3b期、双盲、安慰剂对照研究评估了阿普斯特对中度至重度头皮银屑病的疗效和安全性,研究结果已发表于 J Am Acad Dermatol。

许多银屑病患者被头皮等部位的瘙痒症状所困扰。近日,一项3b期、双盲、安慰剂对照研究评估了阿普斯特对中度至重度头皮银屑病的疗效和安全性,研究结果已发表于 J Am Acad Dermatol。

研究纳入了中度至重度头皮银屑病、对至少一种头皮银屑病外用疗法反应不充分/不耐受的303名成人患者。主要终点是在第16周达到医师的全球评估反应的患者比例,定义为0分(清晰)或1分(几乎清晰),至少减少2分。次要终点包括在第16周,全身瘙痒和头皮瘙痒数字评分量表(NRSs)比基线至少改善4分,以及皮肤科生活质量指数(DLQI)的平均改善。

 

患者随机分组,安慰剂组:n = 102,阿普利司特组:n = 201。阿普斯特的使用使得明显更多的患者达到了头皮全球评估反应(43.3% vs 13.7%)、头皮瘙痒NRS(47.1% vs 21.1%)和全身瘙痒NRS(45.5% vs 22.5%)的反应,并且与安慰剂相比,DLQI的改善明显更大(-6.7 vs -3.8;所有P < .0001)。阿普斯特的常见不良事件是腹泻(30.5%)、恶心(21.5%)、头痛(12.0%)和呕吐(5.5%)。

综上所述,该研究结果表明,阿普斯特可有效治疗中度至重度头皮银屑病。研究的局限性在于未纳入轻度银屑病患者。

 

原始出处:

 

Abby S Van Voorhees, et al., Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: Results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study. J Am Acad Dermatol. 2020 Jul;83(1):96-103. doi: 10.1016/j.jaad.2020.01.072.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1651980, encodeId=e1511651980ea, content=<a href='/topic/show?id=3a3e1e9504' target=_blank style='color:#2F92EE;'>#ACA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1795, encryptionId=3a3e1e9504, topicName=ACA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=843c24278901, createdName=lishizhe, createdTime=Wed Sep 29 09:02:23 CST 2021, time=2021-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2066031, encodeId=caaf2066031ce, content=<a href='/topic/show?id=14109e840d4' target=_blank style='color:#2F92EE;'>#阿普斯特#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97840, encryptionId=14109e840d4, topicName=阿普斯特)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=89da2500024, createdName=1194695146_61857347, createdTime=Mon Feb 28 15:02:23 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973771, encodeId=3b3e9e377113, content=谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b385518453, createdName=ms9000000910064893, createdTime=Tue Jun 15 16:51:59 CST 2021, time=2021-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619603, encodeId=b9071619603d8, content=<a href='/topic/show?id=8dd46061824' target=_blank style='color:#2F92EE;'>#有效治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60618, encryptionId=8dd46061824, topicName=有效治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Wed May 05 13:02:23 CST 2021, time=2021-05-05, status=1, ipAttribution=)]
    2021-09-29 lishizhe
  2. [GetPortalCommentsPageByObjectIdResponse(id=1651980, encodeId=e1511651980ea, content=<a href='/topic/show?id=3a3e1e9504' target=_blank style='color:#2F92EE;'>#ACA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1795, encryptionId=3a3e1e9504, topicName=ACA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=843c24278901, createdName=lishizhe, createdTime=Wed Sep 29 09:02:23 CST 2021, time=2021-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2066031, encodeId=caaf2066031ce, content=<a href='/topic/show?id=14109e840d4' target=_blank style='color:#2F92EE;'>#阿普斯特#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97840, encryptionId=14109e840d4, topicName=阿普斯特)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=89da2500024, createdName=1194695146_61857347, createdTime=Mon Feb 28 15:02:23 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973771, encodeId=3b3e9e377113, content=谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b385518453, createdName=ms9000000910064893, createdTime=Tue Jun 15 16:51:59 CST 2021, time=2021-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619603, encodeId=b9071619603d8, content=<a href='/topic/show?id=8dd46061824' target=_blank style='color:#2F92EE;'>#有效治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60618, encryptionId=8dd46061824, topicName=有效治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Wed May 05 13:02:23 CST 2021, time=2021-05-05, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1651980, encodeId=e1511651980ea, content=<a href='/topic/show?id=3a3e1e9504' target=_blank style='color:#2F92EE;'>#ACA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1795, encryptionId=3a3e1e9504, topicName=ACA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=843c24278901, createdName=lishizhe, createdTime=Wed Sep 29 09:02:23 CST 2021, time=2021-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2066031, encodeId=caaf2066031ce, content=<a href='/topic/show?id=14109e840d4' target=_blank style='color:#2F92EE;'>#阿普斯特#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97840, encryptionId=14109e840d4, topicName=阿普斯特)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=89da2500024, createdName=1194695146_61857347, createdTime=Mon Feb 28 15:02:23 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973771, encodeId=3b3e9e377113, content=谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b385518453, createdName=ms9000000910064893, createdTime=Tue Jun 15 16:51:59 CST 2021, time=2021-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619603, encodeId=b9071619603d8, content=<a href='/topic/show?id=8dd46061824' target=_blank style='color:#2F92EE;'>#有效治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60618, encryptionId=8dd46061824, topicName=有效治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Wed May 05 13:02:23 CST 2021, time=2021-05-05, status=1, ipAttribution=)]
    2021-06-15 ms9000000910064893

    谢谢

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1651980, encodeId=e1511651980ea, content=<a href='/topic/show?id=3a3e1e9504' target=_blank style='color:#2F92EE;'>#ACA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1795, encryptionId=3a3e1e9504, topicName=ACA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=843c24278901, createdName=lishizhe, createdTime=Wed Sep 29 09:02:23 CST 2021, time=2021-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2066031, encodeId=caaf2066031ce, content=<a href='/topic/show?id=14109e840d4' target=_blank style='color:#2F92EE;'>#阿普斯特#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97840, encryptionId=14109e840d4, topicName=阿普斯特)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=89da2500024, createdName=1194695146_61857347, createdTime=Mon Feb 28 15:02:23 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973771, encodeId=3b3e9e377113, content=谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b385518453, createdName=ms9000000910064893, createdTime=Tue Jun 15 16:51:59 CST 2021, time=2021-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619603, encodeId=b9071619603d8, content=<a href='/topic/show?id=8dd46061824' target=_blank style='color:#2F92EE;'>#有效治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60618, encryptionId=8dd46061824, topicName=有效治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Wed May 05 13:02:23 CST 2021, time=2021-05-05, status=1, ipAttribution=)]

相关资讯

Lancet Rheumatol:TYK2抑制剂PF-06826647治疗银屑病的疗效和安全性

酪氨酸激酶2(TYK2)信号阻滞已被证实对银屑病具有一定治疗潜能。该研究的主要目的是评估TYK2抑制剂PF-06826647的安全性和耐受性。

JAMA Dermatol:银屑病,是否会影响女性正常怀孕生育?

银屑病(牛皮癣)是一种免疫介导的慢性炎性皮肤病,会影响女性怀孕生育吗?

J Allergy Clin Immunol:研究确定与银屑病患者COVID-19不良结局相关的因素

银屑病患者的多病负担和系统性免疫抑制剂的使用可能会增加COVID-19的不良预后风险。近日,研究人员描述了银屑病患者COVID-19的病程特点,并确定了与住院相关的因素,研究结果已发表于J Aller

Br J Dermatol:60万+人群队列研究揭示炎性皮肤病与慢性肾病风险的相关性

炎性皮肤病与慢性肾脏疾病(CKD)风险真的有关联吗

中重度斑块型银屑病治疗药物依奇珠单抗临床III期研究(RHBH)中国人群取得积极主要研究结果

拓咨®(依奇珠单抗)在中国患者中耐受性良好,未发现新的安全性信号。

Int J Environ Res Public Health:银屑病能够增加突发感音神经性听力损失的风险

银屑病是一种著名的免疫介导的疾病。其自身免疫病理生理学与免疫介导的系统性血管假说中关于突发感音神经性听力损失(SSNHL)的发病机制是一致的。

Baidu
map
Baidu
map
Baidu
map